These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 30818144)

  • 101. Triple‑negative breast cancer therapy: Current and future perspectives (Review).
    Won KA; Spruck C
    Int J Oncol; 2020 Dec; 57(6):1245-1261. PubMed ID: 33174058
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
    Nomura H; Kataoka F; Aoki D; Jinno H; Kitagawa Y; Sato Y; Womack C; Wombwell H; Hodgson D; O'Connor M; Harbron C; Yin X
    Cancer Biomark; 2016; 16(1):145-52. PubMed ID: 26577420
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Homologous recombination deficiency (HRD) is associated with better prognosis and possibly causes a non-inflamed tumour microenvironment in nasopharyngeal carcinoma.
    Zhou X; Ying H; Sun Y; Zhang W; Luo P; Zhu S; Zhang J
    J Pathol Clin Res; 2024 Sep; 10(5):e12391. PubMed ID: 39104056
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score.
    Feng C; Zhang Y; Wu F; Li J; Liu M; Lv W; Li C; Wang W; Tan Q; Xue X; Ma X; Zhang S
    Breast; 2023 Jun; 69():392-400. PubMed ID: 37116400
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    da Cunha Colombo Bonadio RR; Fogace RN; Miranda VC; Diz MDPE
    Clinics (Sao Paulo); 2018 Aug; 73(suppl 1):e450s. PubMed ID: 30133561
    [TBL] [Abstract][Full Text] [Related]  

  • 107. [BRCA1/2 gene mutation and clinicopathologic features of triple negative breast cancer].
    Ma ZP; Wang W; Zhang W
    Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):397-400. PubMed ID: 27256048
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Integrated molecular profiling of young and elderly patients with triple-negative breast cancer indicates different biological bases and clinical management strategies.
    Ma D; Jiang YZ; Xiao Y; Xie MD; Zhao S; Jin X; Xu XE; Shao ZM
    Cancer; 2020 Jul; 126(14):3209-3218. PubMed ID: 32383785
    [TBL] [Abstract][Full Text] [Related]  

  • 109. A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.
    Wang Y; Park JYP; Pacis A; Denroche RE; Jang GH; Zhang A; Cuggia A; Domecq C; Monlong J; Raitses-Gurevich M; Grant RC; Borgida A; Holter S; Stossel C; Bu S; Masoomian M; Lungu IM; Bartlett JMS; Wilson JM; Gao ZH; Riazalhosseini Y; Asselah J; Bouganim N; Cabrera T; Boucher LM; Valenti D; Biagi J; Greenwood CMT; Polak P; Foulkes WD; Golan T; O'Kane GM; Fischer SE; Knox JJ; Gallinger S; Zogopoulos G
    Clin Cancer Res; 2020 Oct; 26(20):5462-5476. PubMed ID: 32816949
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
    Börcsök J; Diossy M; Sztupinszki Z; Prosz A; Tisza V; Spisak S; Rusz O; Stormoen DR; Pappot H; Csabai I; Brunak S; Mouw KW; Szallasi Z
    Clin Cancer Res; 2021 Jul; 27(13):3734-3743. PubMed ID: 33947694
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors.
    Garutti M; Pelizzari G; Bartoletti M; Malfatti MC; Gerratana L; Tell G; Puglisi F
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295913
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
    Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
    Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Tumor
    Afghahi A; Timms KM; Vinayak S; Jensen KC; Kurian AW; Carlson RW; Chang PJ; Schackmann E; Hartman AR; Ford JM; Telli ML
    Clin Cancer Res; 2017 Jul; 23(13):3365-3370. PubMed ID: 28087643
    [No Abstract]   [Full Text] [Related]  

  • 114. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    Kristeleit RS; Miller RE; Kohn EC
    Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

  • 116. BRCAness as a prognostic indicator in patients with early breast cancer.
    Liu L; Matsunaga Y; Tsurutani J; Akashi-Tanaka S; Masuda H; Ide Y; Hashimoto R; Inuzuka M; Watanabe C; Taruno K; Sawada T; Okuyama H; Ata A; Kuwayama T; Nakayama S; Tonouchi Y; Nakamura S
    Sci Rep; 2020 Dec; 10(1):21173. PubMed ID: 33273622
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer.
    Gong R; Ma Z; He L; Jiang S; Cao D; Cheng Y
    Chem Biol Interact; 2023 Sep; 382():110567. PubMed ID: 37271214
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
    Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
    Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.